Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
raleigh-durham blog main
9
×
raleigh-durham top stories
biotech
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boston blog main
indiana blog main
indiana top stories
national top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
national
amgen
cancer
fda
merck
purdue pharma
bristol-myers squibb
diagnostics
eli lilly
europe blog main
europe top stories
glaxosmithkline
hepatitis b
What
drug
9
×
bio
fda
new
roundup
approval
cancer
decades
friday
immunotherapy
market
migraine
patients
plan
pricing
won
acquisitions
activity
acute
addresses
advanced
advantages
agency
aimmune
allergy
anathema
approved
arrival
awaited
award
awarded
bar
biggest
biotech
brings
build
buy
causes
ceo
cholesterol
Language
unset
9
×
Current search:
drug
×
unset
×
" raleigh-durham blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs